These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 8405032)

  • 1. Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol.
    Leemann TD; Devi KP; Dayer P
    Eur J Clin Pharmacol; 1993; 45(1):65-71. PubMed ID: 8405032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.
    Ayesh R; Dawling S; Hayler A; Oates NS; Cholerton S; Widdop B; Idle JR; Smith RL
    Chirality; 1991; 3(1):14-8. PubMed ID: 2039678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2D6-dependent metabolism on the steady-state pharmacokinetics and pharmacodynamics of metoprolol and nicardipine, alone and in combination.
    Laurent-Kenesi MA; Funck-Brentano C; Poirier JM; Decolin D; Jaillon P
    Br J Clin Pharmacol; 1993 Dec; 36(6):531-8. PubMed ID: 12959269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
    Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
    Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype.
    Lennard MS; Tucker GT; Woods HF; Silas JH; Iyun AO
    Br J Clin Pharmacol; 1989 May; 27(5):613-6. PubMed ID: 2757883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.
    Brøsen K; Gram LF; Haghfelt T; Bertilsson L
    Pharmacol Toxicol; 1987 Apr; 60(4):312-4. PubMed ID: 3588528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies.
    McGourty JC; Silas JH; Lennard MS; Tucker GT; Woods HF
    Br J Clin Pharmacol; 1985 Dec; 20(6):555-66. PubMed ID: 2868742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.
    Lennard MS; Tucker GT; Woods HF
    Clin Pharmacokinet; 1986; 11(1):1-17. PubMed ID: 2868819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects.
    Lewis RV; Ramsay LE; Jackson PR; Yeo WW; Lennard MS; Tucker GT
    Br J Clin Pharmacol; 1991 Apr; 31(4):391-8. PubMed ID: 2049246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs.
    Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; Ingelman-Sundberg M
    Eur J Clin Pharmacol; 1996; 51(2):117-22. PubMed ID: 8911874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine inhibits the 7-hydroxylation of chlorpromazine in extensive metabolisers of debrisoquine.
    Muralidharan G; Cooper JK; Hawes EM; Korchinski ED; Midha KK
    Eur J Clin Pharmacol; 1996; 50(1-2):121-8. PubMed ID: 8739822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.
    al-Hadidi HF; Irshaid YM; Rawashdeh NM
    Eur J Clin Pharmacol; 1994; 47(4):311-4. PubMed ID: 7875180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose quinidine treatment inhibits mexiletine oxidation in extensive metabolizers of debrisoquine.
    Broly F; Vandamme N; Caron J; Libersa C; Lhermitte M
    Life Sci; 1991; 48(26):PL123-8. PubMed ID: 2046473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.
    Leemann T; Dayer P; Meyer UA
    Eur J Clin Pharmacol; 1986; 29(6):739-41. PubMed ID: 3709620
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.